Eupraxia Pharmaceuticals Inc.
EPRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.08 | -0.15 | 0.10 | -0.01 |
| FCF Yield | -27.98% | -22.08% | -18.99% | -22.44% |
| EV / EBITDA | -2.08 | -3.09 | -3.61 | -2.45 |
| Quality | ||||
| ROIC | -121.70% | -245.78% | -80.35% | -50.32% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.17 | 0.72 | 0.76 | 0.64 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -44.55% | -42.32% | -22.77% | -2,851.32% |
| Safety | ||||
| Net Debt / EBITDA | 0.92 | 0.32 | 0.70 | 0.63 |
| Interest Coverage | -44.74 | -23.80 | -17.92 | -14.40 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |